( TorontoVE:ICO )

News from iCo Therapeutics Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 24, 2015, 19:21 ET iCo Therapeutics Announces Third Quarter 2015 Financial Results

VANCOUVER, Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for...


Nov 28, 2014, 17:00 ET iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update

VANCOUVER, Nov. 28, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for...


Nov 04, 2014, 07:00 ET iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS

VANCOUVER, Nov. 4, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced that...


Oct 22, 2014, 07:00 ET iCo Therapeutics Announces Advancement of Oral Amphotericin B Program

VANCOUVER, Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced next steps for...


Aug 29, 2014, 07:00 ET iCo Therapeutics Announces Second Quarter 2014 Financial Results

VANCOUVER, Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for...


Aug 19, 2014, 07:00 ET iCo Therapeutics Announces Positive Oral Amphotericin B Study Results

VANCOUVER, Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported results...


Jun 30, 2014, 07:00 ET iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders

VANCOUVER, June 30, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced that all...


Jun 09, 2014, 08:00 ET iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema

VANCOUVER, June 9, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced top-line...


May 29, 2014, 17:00 ET iCo Therapeutics Announces First Quarter 2014 Financial Results

VANCOUVER, May 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results...


Apr 29, 2014, 07:00 ET iCo Therapeutics Announces Poster Presentation at ARVO

VANCOUVER, April 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced that research...


Apr 24, 2014, 17:00 ET iCo Therapeutics Announces Year End 2013 Financial Results

VANCOUVER, April 24, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results...


Jan 27, 2014, 10:03 ET iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing

VANCOUVER, Jan. 27, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) announced today that it has...


Jan 21, 2014, 17:00 ET iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering

VANCOUVER, Jan. 21, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or the "Company") (TSXV: ICO) (OTCQX: ICOTF) announced today that it has...


Dec 20, 2013, 07:00 ET iCo Therapeutics Begins Trading on the OTCQX Marketplace

VANCOUVER, Dec. 20, 2013 /PRNewswire/ - iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF), announced that its common shares will begin trading today on...


Dec 12, 2013, 11:42 ET iCo Therapeutics Announces Program and Intellectual Property Advancements for Oral Amphotericin B

VANCOUVER, Dec. 12, 2013 /PRNewswire/ - iCo Therapeutics (TSX-V: ICO), today announced that on November 26, 2013, U.S. patent 8,592,382 was...


Sep 05, 2013, 17:06 ET iCo Therapeutics Grants Options to a Director

VANCOUVER, Sept. 5, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO), today announced that on September 5, 2013 the...


Sep 04, 2013, 07:00 ET iCo Therapeutics to Present at the Rodman & Renshaw 2013 Annual Global Investment Conference

VANCOUVER, Sept. 4, 2013 /PRNewswire/ - iCo Therapeutics Inc. (TSX-V: ICO), today announced it will be presenting at the Rodman & Renshaw...


Aug 26, 2013, 17:00 ET iCo Therapeutics Announces Second Quarter 2013 Financial Results

VANCOUVER, Aug. 26, 2013 /PRNewswire/ - iCo Therapeutics (TSX-V: ICO), today reported financial results for the quarter ended June 30, 2013....


Jun 18, 2013, 07:00 ET iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema

VANCOUVER, June 18, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) announced today that it has completed...


Sep 26, 2011, 07:45 ET iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema

VANCOUVER, Sept. 26, 2011 /PRNewswire/ - iCo Therapeutics Inc. (TSXV: ICO) today announced that the company has entered into a research...


Feb 09, 2009, 16:30 ET iCo Therapeutics Closes $1.3 Million Private Placement

VANCOUVER, Feb. 9 /PRNewswire-FirstCall/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce the completion of a $1,292,500 non-brokered...


Jan 22, 2007, 00:00 ET iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema

VANCOUVER, Jan. 22 /PRNewswire/ - iCo Therapeutics Inc. announced today that the United States Food and Drug Administration (FDA) has accepted...


Oct 27, 2006, 01:00 ET iCo Therapeutics Welcomes Dr. David S. Boyer to Strategic Advisory Board

VANCOUVER, Oct. 27 /PRNewswire/ - iCo Therapeutics Inc. announced today that Dr. David S. Boyer will join its strategic advisory team. As an...


Jun 28, 2006, 01:00 ET iCo Therapeutics Welcomes Dr. Jason Slakter to Strategic Advisory Board

VANCOUVER, June 28 /PRNewswire/ - iCo Therapeutics Inc. announced today that Dr. Jason Slakter will join its strategic advisory team. An...


Jun 14, 2006, 01:00 ET iCo Therapeutics Recruits Leading Ophthalmologist to Strategic Advisory Board

VANCOUVER, June 14 /PRNewswire/ - iCo Therapeutics Inc. announced today that Dr. Philip Rosenfeld has joined iCo's strategic advisory team. Dr....